InvestorsHub Logo
Followers 14
Posts 1305
Boards Moderated 0
Alias Born 06/05/2007

Re: None

Thursday, 01/02/2020 6:21:39 PM

Thursday, January 02, 2020 6:21:39 PM

Post# of 626
Is biogen looking at Promis Neurosciences PMN310? Similar product, but better specificity and binding affinity than aducanumab. I haven't found comparative studies vs BAN2401, but their website claims lower ARIA-E effects (so you could dose higher and more efficiently). They claim they will start PhI in 2020... we'll see.

The company is tiny, publicly traded, market cap of only $34M. Biogen's stock went up about $15B on marginal PhII aducanumab results, if I recall.

US ticker is ARFXF

https://promisneurosciences.com/

Any dd appreciated, thx.

God grant me the serenity to deal with the things I cannot change; courage to change the things I can and should; and wisdom to know the difference.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BIIB News